***  Sold Out!  ***


You are cordially invited to a dinner party on October 10, 2015, in the West Village, New York City.

Join us for an evening featuring good food, fine wine, warm hospitality, and the company of like-minded individuals. Share your views and help shape the public discourse about the role of psychedelics in medicine, therapy, and healing.

Enjoy intimate conversation with MAPS Founder and Executive Director Rick Doblin, Ph.D., during this unique opportunity to learn about the path to legalizing psychedelic medicine.

MAPS is currently conducting clinical research into MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD), a serious medical condition that is notoriously challenging to treat effectively. In ongoing controlled clinical trials, the administration of MDMA-assisted psychotherapy is helping some study participants overcome treatment- resistant PTSD. As research into MDMA-assisted psychotherapy continues with promising results, we are approaching a new phase of research that will require more clinical sites, more therapists, more patients, and more support.

With your help, we can improve public perception of psychedelics and raise the bar for PTSD treatment.
Proceeds from the dinner benefit MAPS psychedelic research and education projects.

Special guests to be announced.

Doors open at 7:00pm.

Dinner served at 8:00pm.

Special thanks to Giancarlo Canavesio and Stephanie Long, and to host committee members Bailey Gimbel, Sir Ivan, Josh Mailman & Monica Winsor, Sam Victor Tabar, Michael & Devera Witkin (committee in formation).

For more information, contact Merete Christiansen at (831) 429-6362 or
Learn about our research and other events at

About PTSD

Posttraumatic stress disorder (PTSD) affects 18% of U.S. veterans, and 3% of the general population in the U.S. Current treatments provide limited relief. Join us to find out about our promising therapy, and how substances that produce altered states can be catalysts for emotional and psychological healing. In MAPS' pilot study, 83% of subjects receiving MDMA-assisted psychotherapy did not qualify for PTSD after treatment, and the benefits were sustained an average of 3.8 years later.

About MAPS

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD. Ongoing studies are taking place in Boulder, Colorado; Charleston, South Carolina; Tel Aviv, Israel, and Vancouver, Canada.


This event takes place during the Horizons: Perspectives on Psychedelics conference in New York, Oct. 9-11, 2015.